Recce Pharmaceuticals (ASX: RCE) — Company Overview, News & Financial Data
Recce Pharmaceuticals is a biotechnology company developing a new class of synthetic anti-infectives to address antibiotic-resistant superbugs and viral pathogens.
Recce Pharmaceuticals
Recce Pharmaceuticals is a biotechnology company developing a new class of synthetic anti-infectives to address antibiotic-resistant superbugs and viral pathogens. The company's lead synthetic polymer compounds are engineered to maintain potency without inducing cellular resistance, offering potential treatments for life-threatening microbial infections. Recce Pharmaceuticals advances multiple clinical development programs, including intravenous formulations for systemic conditions such as sepsis and urosepsis, and topical applications for acute bacterial skin infections, burn wounds, and diabetic foot ulcers. The company conducts clinical trials across Australia and international jurisdictions while operating specialized manufacturing capabilities to supply synthetic candidates for ongoing regulatory trials.
Snapshot
Operations
Products and/or services of Recce Pharmaceuticals
- Intravenous Anti-Infective Therapy: Formulation administered via intravenous infusion targeting serious systemic infections, including sepsis and urosepsis, currently undergoing Phase 2 clinical trials across clinical sites in Australia to evaluate safety, efficacy, and dosage profiles.
- Topical Burn Wound Anti-Infective: Gel-based synthetic polymer formulation developed for topical application to treat acute bacterial skin and skin structure infections, including burn wound infections, undergoing clinical evaluation in Australian hospital centers.
- Diabetic Foot Infection Anti-Infective: Topical synthetic compound designed for treating complicated diabetic foot ulcers and associated bacterial infections, evaluated in registrational clinical trials in Indonesia and Australia to address multidrug-resistant pathogens.
- Urinary Tract Infection Therapeutics: Systemic anti-infective program evaluating intravenous delivery for complicated urinary tract infections, targeting acute and recurrent uropathogenic bacterial strains resistant to conventional antibiotic treatments in Phase 2 clinical trials.
- Anti-Viral Synthetic Candidates: Pre-clinical and early-stage development program evaluating synthetic polymer compounds against viral pathogens, focusing on broad-spectrum anti-viral activity and universal mechanisms of action against rapidly mutating viral pathogen strains.
- Automated Manufacturing Operations: In-house clinical manufacturing facility located in Macquarie Park, Sydney, Australia, supporting automated pilot-scale batch production, quality testing, and supply of synthetic anti-infective formulations for ongoing clinical trials.
Recce Pharmaceuticals executive team
- Dr. John K. A. Prendergast Ph.D.Executive Chairman of the Board
- Mr. James Hamilton-Bray Graham GAICDCEO, MD & Executive Director
- Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci)Chief Scientific Director & Executive Director
- Dr. Justin WardPrincipal Quality Chemist & Executive Director
- Mr. Arthur KollarasPrincipal Engineer & Head of Manufacturing
- Dr. Alan W. Dunton B.Sc., M.D.Chief Medical Advisor & Independent Non Executive Director
- Mr. Justin ReynoldsChief Financial Officer
- Mr. Daniel Astudillo B.A., B.Com., M.B.A.Head of Marketing
- Ms. Maggie NiewidokCompany Secretary